Osteoclastic giant cell variant of urothelial carcinoma in a COVID- positive patient: A rare variant in an unusual circumstances
Article Sidebar
Main Article Content
Abstract
Bladder carcinomas have a great propensity for divergent differentiation with more that 90% being Transitional cell carcinoma. Several histological variants have been have described so far; they are not only morphologically unique but also have significant prognostic and therapeutic differences making their timely identification of paramount importance. Osteoclastic giant cell variant of urothelial carcinoma is very rare type with controversial management. Studies from China have documented higher incidence and severity of illness in COVID-19 positive cancer patients. We report an unusual case of Osteoclastic giant cell variant of urothelial carcinoma in a 63 yrs old male patient associated with simultaneous COVID-19 infection.
Article Details
Copyright (c) 2021 Rana C, et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Samaratunga H, Delahunt B. Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology (Phila). 2012; 44: 407–418. PubMed: https://pubmed.ncbi.nlm.nih.gov/22777074/
Baydar D, Amin MB, Epstein JI. Osteoclast-rich undifferentiated carcinomas of the urinary tract. Mod Pathol. 2006; 19: 161–171. PubMed: https://pubmed.ncbi.nlm.nih.gov/16322750/
Liang W, Guan W, Chen R, Wang W, Li J, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335–337. PubMed: https://pubmed.ncbi.nlm.nih.gov/32066541/
Wang D, Hu B, Hu C, Zhu F, Liu X, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069. PubMed: https://pubmed.ncbi.nlm.nih.gov/32031570/
Osman C, Muammer B, Murat O, Tamer A, Fatih A. Osteoclast-type giant cell carcinoma of the urinary bladder: An unusual and aggressive variant of urothelial carcinoma. Urol Case Rep. 2019; 23: 50–51. PubMed: https://pubmed.ncbi.nlm.nih.gov/30581755/
Akatsu T, Kameyama K, Kawachi S, Tanabe M, Aiura K, et al. Gallbladder carcinoma with osteoclast-like giant cells. J Gastroenterol. 2006; 41: 83–87. PubMed: https://pubmed.ncbi.nlm.nih.gov/16501862/
Kimura K, Ohnishi Y, Morishita H, Amezaki M, Irikura H. Giant cell tumor of the kidney. Virchows Arch A Pathol Anat Histopathol. 1983; 398: 357–365. PubMed: https://pubmed.ncbi.nlm.nih.gov/6402846/
Oda Y, Sakamoto A, Saito T, Matsuda S, Tanaka K, et al. Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology. 2001; 39: 629–637. PubMed: https://pubmed.ncbi.nlm.nih.gov/11903582/
Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000; 13: 1186–1191. PubMed: https://pubmed.ncbi.nlm.nih.gov/11106075/
Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, et al. A populationbased study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004; 90: 1572–1576. PubMed: https://pubmed.ncbi.nlm.nih.gov/15083187/
Patel K, Choudhury A, Hoskin P, Varughese M, James N, et al. Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review. Clin Oncol. 2020; 32: 347–353. PubMed: https://pubmed.ncbi.nlm.nih.gov/32389318/
Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17: 519-527. PubMed: https://pubmed.ncbi.nlm.nih.gov/32944387/
Barcellini A, Filippi AR, Dal Mas F, Cobianchi L, Corvò R, et al. To a new normal in radiation oncology: looking back and planning forward. Tumori. 2020; 106: 440-444. PubMed: https://pubmed.ncbi.nlm.nih.gov/33045932/